Publikationen

 

Wesentliche Arbeiten wurden in folgenden Zeitschriften publiziert:

Kidney International

Journal American Society of Nephrology

Circulation

Circulation Research

Journal of Biological Chemistry

Hypertension

Arteriosclerosis, Thrombosis and Vascular Biology

Atherosclerosis

Nephrology, Dialysis, Transplantation

European Journal of Pharmacology

British Journal of Pharmacology

FEBS Letters

FASEB Journal

European Heart Journal

Pfügers Archiv European Journal of Physiology

Nephron

European Journal of Clinical Investigation

Nieren und Hochdruckkrankheiten

Basic Research in Cardiology

Eicosanoids

Molecular Pharmacology

Clin Immunotherapie

Kidney Blood Pressure Res

 

Publikationsverzeichnis

Originalarbeiten

Übersichtsarbeiten

Buchartikel

 

 Originalarbeiten

1.       Galle J, Bassenge E, Busse R. Oxidized low density lipoproteins potentiate vasoconstrictions to various agonists by direct
     interaction with vascular smooth muscle. Circ Res 1990;66:1287-1293.

 

2.       Galle J, Lückhoff A, Busse R, Bassenge E. Low-density lipoproteins stimulate internal free calcium and prostacyclin release
     in endothelial cells. Eicosanoids 1990;3:81-86.

 

3.  Galle J, Mülsch A, Busse R, Bassenge E. Effects of native and oxidized low density lipoproteins on formation and
     inactivation of EDRF. Arterioscler Thromb 1991;11:198-203.

 

4.  Galle J, Bassenge E. Influence of low-density lipoproteins (LDL) on the reactivity of atherosclerotic arteries. Z Kardiol
     1991;80:15-20.

 

5.  Galle J, Bassenge E. Effects of native and oxidized low density lipoproteins on endothelium-dependent and endothelium-
     independent vasomotion. Basic Res Cardiol1991;86:127-142.

 

6.  Galle J, Busse R, Bassenge E. Hypercholesterolemia and atherosclerosis change vascular reactivity in rabbits by different
     mechanisms. Arterioscler Thromb 1991;11:1712-1718.

 

7.  Galle J, Bauersachs J, Busse R, Bassenge E. Inhibition of cyclic AMP-mediated and cyclic GMP- mediated dilations in
     isolated arteries by oxidized low density lipoproteins. Arterioscler Thromb1992;12:180-186.

 

8.  Galle J, Schenck I, Schollmeyer P, Wanner C. Cyclosporine and oxidized lipoproteins affect vascular reactivity: Influence of
     the endothelium. Hypertension1993;21:315-321.

9.  Galle J, Bauersachs J, Bassenge E, Busse R. Arterial size determines the enhancement of contractile responses after
     suppression of endothelium-derived relaxing factor formation. Pflugers Arch1993;422:564-569.

10.     Galle J, Schollmeyer P, Wanner C. Cyclosporine and oxidized low density lipoproteins synergistically potentiate
      vasoconstriction: influence of the endothelium. Eur Heart J 1993;14:111-117.

 

11. Galle J, Öchslen M, Schollmeyer P, Wanner C. Oxidized lipoproteins inhibit endothelium-dependent vasodilation: Effects of
      pressure and high-density lipoprotein. Hypertension 1994;23:556-564.

 

12.     Galle J, Bengen J, Schollmeyer P, Wanner C. Oxidized lipoprotein(a) inhibits endothelium-dependent dilation:   Prevention
      by high density lipoprotein. Eur J Pharmacol 1994;265:111-115.

 

13.     Galle J, Herzog C, Schollmeyer P, Wanner C. Oxygen-derived radicals stimulate renin release of isolated juxtaglomerular
       cells.
FEBS Letters 1994;351:314-316.

14.     Galle J, Öchslen M, Schollmeyer P, Wanner C. Hemmung der endothelabhängigen Dilatation durch oxidierte LDL: Einflub
       von transmuralem Druck und Prävention durch HDL. Nieren- und Hochdruckkrankheiten 1995;24:31-33.

15.     Galle J, Stunz P, Schollmeyer P, Wanner C. Oxidized LDL and lipoprotein(a) stimulate renin release of juxtaglomerular cells.
     
Kidney Int 1995;47:45-52.

16.     Galle J, Bengen J, Schollmeyer P, Wanner C. Impairment of endothelium-dependent dilation in rabbit renal arteries by
      oxidized lipoprotein(a) -  Role of oxygen-derived radicals. Circulation 1995;92:1582-1589.
[PDF]

17.     Galle J, Schini V, Stunz P, Wanner C, Schollmeyer P. Interleukin-1b induces the formation of nitric oxide in isolated
      juxtaglomerular cells: influence on renin secretion. Nephrol Dial Transplant 1995;10:191-197.


18. Pohl U, Heydari N, Galle J. Effects of LDL on intracellular free calcium and nitric oxide-dependent cGMP formation in porcine
      endothelial cells.
Atherosclerosis 1995;117:169-178. [PDF]

19. Dimmeler S, Haendeler J, Galle J, Zeiher AM.
Oxidized low density lipoprotein induces apoptosis of human endothelial cells
       by activation of CPP32-like proteases: a mechanistic clue to the "response to injury" hypothesis. Circulation 1997;95:1760-
       1763.
[PDF]

20. Galle J, Heinloth A, Schwedler S, Wanner C. Effect of HDL and atherogenic lipoproteins on formation of O2- and renin
      release in juxtaglomerular cells. Kidney Int 1997;51:253-260.

21. Greiber S, Weber U, Galle J, Brämer P, Schollmeyer P. Activated clotting time is not a sensitive parameter to monitor
      anticoagulation with low molecular weight heparin in hemodialysis.
Nephron 1997;76:15-19.

22. Krämer-Guth A, Quaschning T, Galle J, Baumstark MW, Königer M, Nauck M, Schollmeyer P, März W, Wanner C.
     
Structural and compositional modifications of diabetic low- density lipoproteins influence their receptor-mediated uptake by
      hepatocytes. European Journal of Clinical Investigation 1997;27:460-468.

23. Krämer-Guth A, Quaschning T, Baumstark MW, Pavenstädt H, Galle J, Nauck M, Schollmeyer P, März W, Wanner C.
      Uptake and metabolism of low density lipoproteins from patients with diabetes mellitus type II by glomerular epithelial cells.
      Nephrol Dial Transplant
1997;12:1336-1343.
[PDF]

24. Hug H, Strand S, Grambihler A, Galle J, Hack V, Stremmel W, Krammer PH, Galle PR. Communication - Reactive oxygen
      intermediates are involved in the induction of CD95 ligand mRNA expression by cytostatic drugs in hepatoma cells. J Biol
      Chem
1997;272:28191-28193.
[PDF]

25. Galle J, Winner B, Conzelmann E, Wanner C. Impairment of endothelial function induced by glyc-oxidized Lp(a). Cell Mol
      Biol
1998;44:1035-1045.

26. Galle J, Schneider R, Winner B, Lehmann-Bodem C, Schinzel R, Münch G, Conzelmann E, Wanner C. Glyc-oxidized LDL
       impair endothelial function more potently than oxidized LDL: role of enhanced oxidative stress. Atherosclerosis 1998;138:65-
       77.
[PDF]

27. Walter DH, Haendeler J, Galle J, Zeiher AM, Dimmeler S. Cyclosporin A inhibits apoptosis of human endothelial cells by
      preventing release of cytochrome C from mitochondria.
Circulation 1998;98:1153-1157. [PDF]

28. Dimmeler S, Hermann C, Galle J, Popp R, Goebel C, Zeiher AM.
Upregulation of superoxide dismutase and nitric oxide
       synthase synergize to mediate the apoptosis-suppressive effects of shear stress on endothelial cells. Arterioscler Thromb
       Vasc Biol
1999;19:656-664.
[PDF]

29. Galle J, Zabel U, Hübner U, Hatzelmann A, Wagner B, Wanner C, Schmidt HHHW. Effects of the soluble guanylyl cyclase
      activator, YC-1, on vascular tone, cGMP levels and phosphodiesterase activity. Br J Pharmacol 1999;127:195-203. [
PDF]

30. Morawietz H, Rueckschloss U, Niemann B, Galle J, Hakim K, Zerkowski H-R, Sawamura T, Holtz J, Duerrschmidt N,
      Zerkowski HR. Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low density lipoprotein. Circulation
      1999;100:899-902.
[PDF]

31. Heermeier K, Schneider R, Heinloth A, Wanner C, Dimmeler S, Galle J. Oxidative Stress Mediates Apoptosis Induced by
       oxLDL and oxLp(a). Kidney Int 1999;56:1310-1312.
[PDF]

32. Galle J, Schneider R, Heinloth A, Wanner C, Galle PR, Conzelmann E, Dimmeler S, Heermeier K. Lp(a) and LDL induce
       apoptosis in human endothelial cells and in rabbit aorta - role of oxidative stress  -.  Kidney Int 1999;55:1450-1461.
[PDF]

33. Galle J, Lehmann-Bodem C, Hübner U, Heinloth A, Wanner C. CyA and OxLDL cause endothelial dysfunction in isolated
       arteries through endothelin-mediated stimulation of O2-. Nephrol Dial Transplant 2000;339-346.
[PDF]

34. Heinloth A, Heermeier K, Raff U, Wanner C, Galle J. Stimulation of NADPH Oxidase by oxidized LDL induces proliferation of
      human vascular endothelial cells. J Am Soc Nephrol 2000;11:1819-1825.
[PDF]

35. Sohn H-Y, Raff U, Hoffmann A, Gloe T, Keller M, Heermeier K, Galle J, Pohl U. Differential role of Angiotensin II receptor
      subtypes on endothelial O2-formation. Br J Pharmacol 2000;131:667-672.
[PDF]

36. Bolz SS, Galle J, Derwand R, De Wit C, Pohl U. Oxidized LDL increase the sensitivity of the contractile apparatus in
       isolated resistance arteries for Ca2+ via a Rho- and Rho-kinase-dependent mechanism. Circulation 2000;102:2402-2410.
      
[PDF]

37. Heermeier K, Leicht W, Palmetshofer A, Ullrich M, Wanner C, Galle J. Oxidized LDL suppresses NF-kappaB and overcomes
       protection from apoptosis in activated endothelial cells. J Am Soc Nephrol 2001;12:456-463.
[PDF]

38.  Morawietz H, Duerrschmidt N, Niemann B, Galle J, Sawamura T, Holtz J. Endothelin-1 Induces the OxLDL Receptor LOX-1
       in Human Endothelial Cells. Biochem Biophys Res Commun 2001;284:961-965.
[PDF]

 

39.   Rueckschloss U,  Galle J, Holtz J, Zerkowski H.-R., Morawietz H. Induction of NAD(P)H Oxidase by Oxidized Low-Density
       Lipoprotein in Human Endothelial Cells: Antiatherosclerotic Potential of HMG- CoA Reductase Inhibitor Therapy. Circulation 
       2001;104:1767-1772
[PDF]


40.   Heinloth A., Fischer B, Brüne B, Galle J. Nitric Oxide prevents oxidized LDL-induced, p53 dependent apoptosis in
       macrophages via guanylate cyclase stimulation. Atherosclerosis  2002;162:92-101
[PDF]

 

41. Ibarra C, Galle J, Melichar VO, Mameghani A, Smolenski A, Walter U, Schmidt HHHW. Phosphorylation of blood vessel
        VASP at serine 239 as in vivo marker of endothelial function. Mol Pharmacol 2002;61:312-319.
[PDF]

 

42.   Morawietz H, Duerrschmidt N, Niemann B, Galle J, Sawamura T, Holtz J. Augmented endothelial uptake of oxidized low-   
       density lipoprotein in response to endothelin-1. Clin Science 2002;103:9S-12S.
[PDF]

 

43.   Quaschning T, Kocak S, Wanner C, Bauer C, Neumayer HH, Galle J, Hocher B. Nitric Oxide dependent Regulation

       of Endothelial Function in Endothelin transgenic mice. Nephrol.Dial.Transplant.  2003;18:479-483.[PDF]

 

44.   Schneider R, Raff U, Vornberger N, Schmidt M, Freund R, Reber M, Schramm L, Gambaryan S, Wanner C, Schmidt HHHW, Galle J.

        L-arginine counteracts NO-deficiency and improves the recovery phase of ischemic acute renal failure in rats. Kidney Int

        2003;64:216-225. [PDF].

 

45.   Seibold S, Rudroff C, Weber M, Galle J, Wanner C, Marx M.

        Identification of a new tumor suppressor gene located at chromosome 8p21.3-22. FASEB Journal 2003;17:1180-1182 .[PDF] [PDF]

 

46.   Galle J, Mameghani A, Bolz SS, Gambaryan S, Görg M, Quaschning T, Raff U, Barth H, Seibold S, Wanner C, Pohl U.

        Oxidized LDL and its Compound Lysophosphatidylcholine Potentiate AngII-induced Vasoconstriction by Stimulation of RhoA.

        J Am Soc Nephrol 2003;14:1471-1479. [PDF]

 

47.     Seibold S, Schuerle D, Heinloth A, Wolf G, Wagner M, and Galle J. Oxidized LDL induces proliferation and hypertrophy in human

        endothelial cells via regulation of p27Kip1 expression - role of RhoA. J Am Soc Nephrol 2004;15:3026-3034. [PDF]

 

48.     Fleming I, Mohamed A, Galle J, Brandes RP, Fisslthaler B, and Busse R. Oxidized low-density lipoprotein increases superoxide production

        by endothelial nitric oxide synthase by inhibiting PKC alpha. Cardiovascular Research 2005;65:897-906 [PDF]

 

49.    Quaschning T, Rebhan B, Wunderlich C, Wanner C, Richter C-M, Pfab T, Bauer C, Krämer-Guth A, Galle J, Yanagisawa M, and Hocher B.

        Endothelin B receptor-deficient mice develop salt-induced hypertension independent from endothelial dysfunction independently of salt loading.

        J Hypertens., 2005;23:979-985

 

50.    Raff U, Schneider R, Seibold S, Gambaryan S, Reber M, Vornberger N, Freund R,  Schramm L, Wanner C, and Galle J.

        L-Arginine does not affect renal morphology and cell survival in ischemic acute renal failure in rats. Nephron 2005;101:39-50 [PDF].

 

51.    Schwedler S, Amann K, Wernicke K, Krebs A, Nauck M,  Wanner C, Potempa LA, and Galle J.

        Native C-reactive protein (CRP) increases, whereas modified CRP reduces atherosclerosis in ApoE-knockout-mice. Circulation  2005;112:1016-1023 [PDF].

 

52.    Galle J, Hansen-Hagge T, Wanner C, and Seibold S. Impact of oxidized Low density lipoprotein on vascular cells.
        Atherosclerosis
  2006;185:219-226 [
PDF].

 

53.    Arias-Loza P, Hu K, Schafer A, Bauersachs J, Quaschning T, Galle J, Jazbutyte V, Neyses L, Ertl G, Fritzemeier K,
        Hegele-Hartung C, and Pelzer T. Medroxyprogesterone acetate but not drospirenone ablates the protective function of
        17 beta-estradiol in aldosterone salt-treated rats. Hypertension 2006; 48:994-1001.[
PDF]

54.     Quaschning T, Hocher B, Ruhl S, Kraemer-Guth A, Tilgner J, Wanner C, and Galle J. Vasopeptidase inhibition normalizes
        blood pressure and restores endothelial function in renovascular hypertension. Kidney Blood Press Res. 2006; 29:351-359.

55.     Schwedler S, Filep JG, Galle J, Wanner C, and Potempa LA. C-reactive protein and cardiovascular disease: an alternative
        view for the clinical practice and basic research. Am J Kidney Dis. 2006;47:212-222.[
PDF]

56.     Quaschning T, Voss F, Relle K, Kalk P, Vignon-Zellweger N, Pfab T, Bauer C, Theilig F, Bachmann S, Kraemer-Guth A, Wanner C,
         Theuring F, Galle J, and Hocher B. Lack of Endothelial Nitric Oxide Synthase Promotes Endothelin-Induced Hypertension:
         Lessons from Endothelin-1 Transgenic/Endothelial Nitric Oxide Synthase Knockout Mice. J Am Soc Nephrol 2007;18:730-740.[
PDF]

57.     Schneider R, Sauvant C, Betz B, Otremba M, Fischer D, Holzinger H, Wanner C, Galle J, and Gekle M. Down regulation
         of organic anion transporters OAT1 and OAT3 correlates with impaired secretion of para-aminohippurate after ischemic
         acute renal failure in rats. Am J Physiol Renal Physiol, 2007; 292 F1599-F1605.
 

58.     Schwedler S, Kuhlencordt P, Ponnuswamy P, Hatiboglu G, Quaschning T, Widder J, Wanner C, Potempa L, and Galle J.
          Native C-reactive protein induces endothelial dysfunction in ApoE(-/-) mice: Implications for iNOS and reactive oxygen species.       
          Atherosclerosis 2007; 195:e76-e84
[PDF].

 

59.    Galle J. Reduction of proteinuria with angiotensin receptor blockers. Nat.Clin Pract.Cardiovasc.Med 2008; 5 Suppl 1:S36-S43. [PDF]

 

60.    Hansen-Hagge T, Baumeister E, Bauer T, Schmiedecke D, Wanner C, and Galle J. Transmission of oxLDL-derived lipid peroxide

        radicals into membranes of vascular cells is the main inducer of oxLDL-mediated oxidative stress. Atherosclerosis 2008;197:602-611.[PDF]

 

61.    Quaschning T, Voss F, Herzfeld S, Relle K, Kalk P, Godes M, Pfab T, Kraemer-Guth A, Bonz AW, Theuring F, Galle J, and Hocher B.

        Lack of iNOS impairs endothelial function in endothelin-1 transgenic mice. Kidney Blood Press Res 2008; 31 (2):127-134.
 

62.    Galle J, Schwedhelm E, Pinnetti S, Boger RH, and Wanner C. Antiproteinuric effects of angiotensin receptor blockers: telmisartan

        versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol Dial.Transplant 2008; 23:3174-3183 [PDF]

 

63.    Schwedler S, Hansen-Hagge T, Reichert M, Schmiedeke D, Schneider R, Galle J, Potempa L, Wanner C, and Filep JG. Monomeric

        C-reactive protein decreases acetylated LDL uptake in human endothelial cells. Clin.Chem. 2009; 55 (9):1728-1731.

 

64.    Zuern C, Heimrich J, Kaufmann R, Richter KK, Settmacher U, Wanner C, Galle J, and Seibold S. Down-regulation of MTUS1 in

        human colon tumors. Oncol.Rep. 2010; 23 (1):183-189 [PDF].

 

65.    Galle J, Claes K, Kiss I, Winearls CG, Herlitz H, Guerin A, Di Giulio S, Suranyi MG, Bridges I, Addison J, and
         Farouk M. An observational cohort study of extended dosing (once every 2 weeks or once monthly) regimens
         with darbepoetin alfa in patients with chronic kidney disease not on dialysis: the EXTEND study.
        Nephrol Dial.Transplant 2012; 27:2303-2311 [
PDF].

 

66.    Zuern C, Krenacs L, Starke S, Heimrich J, Palmetshofer A, Holtmann B, Sendtner M, Fischer T, Galle J, 
         Wanner C, and Seibold S. Microtubule associated tumor suppressor 1 deficient mice develop spontaneous heart hypertrophy and SLE-like lymphoproliferative disease.
Int J Oncol. 2012; 40:1079-1088 [PDF].

 

67.    Schimrigk S, Adibi I, Eberl A, Selka I, Galle J, Schmidt S, Fritz H, Fassbender C, Klingel R,
Füchtemann D, Hoffmann F. Immunadsorption zur Eskalation der Schubtherapie bei Multipler Sklerose.
Akt Neurol 2012; 39:174-179 [PDF]

 

68.    Galle J, Kleophas W, Dellanna F, Schmidt V, Forkel C, Dikta G, Krajewski V, Fuchs W, Forst T, Pfützner A. Comparison of the Effects of Pioglitazone versus Placebo when Given in Addition to Standard Insulin Treatment in Patients with Type 2 Diabetes Mellitus Requiring Hemodialysis: Results from the PIOren Study. Nephron Extra 2012; 2:104-114 [PDF]

 

 


 

 










 

 

 

top of the page

 
Übersichtsarbeiten

 

1. Galle J, Wanner C. Modulation renaler Funktionen durch endotheliales Stickoxid - eine alte Substanz neu entdeckt.
       Spektrum Nephrol 1992;5:9-12.

 

2.  Röther E, Galle J, Peter HH. Secondary Raynaud`s Phenomenon. Immun Infekt 1993;21:59-63.

 

3. Wanner C, Galle J, Krämer-Guth A. Lipoprotein metabolism in the nephrotic syndrome. Kid Curr Surv 1994;3:71-76.

 

4. Galle J. Kalzium-Kanal-Blocker und Arteriosklerose. Münch Med Wschr 1995;137:233-236.

 

5. Wanner C, Bartens W, Galle J. Clinical utility of antilipidemic therapies in chronic renal allograft failure. Kidney Int 1995;48
       Suppl. 52:S60-S62.

 

6. Bartens W, Galle J, Wanner C. Lipoprotein(a) bei Dialysepatienten. Mitt Klin Nephrologie 1996;XXV:65-74.

 

7. Galle J, Wanner C. Impact of nitric oxide on renal hemodynamics and glomerular function - modulation by atherogenic
        lipoproteins? Kidney Blood Press Res 1996;19:2-15.

 

8. Wanner C, Galle J. Use of HMG-CoA reductase inhibitors after solid organ transplantation: lipid lowering and immuno-
        suppressive effects. BioDrugs 1997;8:387-393.

 

9. Wanner C, Zimmermann J, Quaschning T, Galle J. Inflammation, dyslipidemia and vascular risk factors in hemodialysis
        patients. Kidney Int 1997;52:S53-S55.

 

10.   Galle J, Wanner C. Oxidative stress and vascular injury - relevant for atherogenesis in uremic patients? Nephrol Dial
        Transplant
1997;12:2480-2483.
[PDF]

 

11.   Galle J. Atherogene Lipoproteine: Wirkung auf Arterientonus und Reninfreisetzung. Fortschritte der Medizin 1998;116:.

 

12.   Wanner C, Greiber S, Krämer-Guth A, Heinloth A, Galle J. Lipids and progression of renal disease: Role of modified low
        density lipoprotein and lipoprotein(a). Kidney Int 1997;52:S102-S106.

 

13.   Galle J, Heermeier K, Wanner C. Atherogenic lipoproteins, oxidative stress, and cell death. Kidney Int 1999;56:62-65.
        
[PDF]

 

14.   Galle J, Wanner C. Modification of lipoproteins in uremia: oxidation, glycation, and carbamylation. Miner Electrolyte Metab
        1999;25:263-268.
[PDF]

 

15.   Galle J, Heermeier K. Angiotensin II and oxidized LDL: an unholy alliance creating oxidative stress. Nephrol Dial Trans-
         plant
1999;14:2585-2589.
[PDF]

 

16.   Galle J, Heinloth A, Wanner C, Heermeier K. Dual effect of oxidized LDL on cell cycle in human endothelial cells through
        oxidative stress. Kidney Int Suppl 2001;59:120-123.
[PDF]

 

17.  Galle J. Oxidative stress in chronic renal failure. Nephrol Dial Transplant 2001;16:2135-2137 [PDF]

 

18.  Galle J, Seibold S. Has the time come to use antioxidant therapy in uremic patients? Nephrol Dial Transplant 2003;18:1452-1455

 

19.  Galle J, Quaschning T, Seibold S, Wanner C. Endothelial dysfunction and inflammation - what is the link? Kidney Int 2003; 63 Sppl. 84:

        S45-S49 [PDF]      

 

20.  Quaschning T, Galle J, Wanner C. Vasopeptidase Inhibition - A New Treatment Approach for Endothelial Dysfunction.
      
 Kidney Int 2003; 63 Sppl. 84:S54-S57 [
PDF]

 

21.  Galle J, Seibold S, Wanner C. Inflammation in uremic patients - what is the link? Kidney Blood Press Res 2003; 26:65-75
        
[PDF] 

 

22. Galle J. Atherosclerosis and arteriitis: implications for therapy of cardiovascular disease. Herz 2004;29:4-11 [PDF]

 

23. Galle J, Seibold S. Antioxidant therapy - should we treat uremic patients? Nieren- und Hochdruckkrankheiten 2004;33:317-322 [PDF]

 

24.  Galle J and Seibold S. Therapy of inflammatory kidney diseases - more than steroids? Internist (Berl) 2004; 45:1388–1394 [PDF].

 

25.  Schwedler S, Filep JG, Galle J, Wanner C, and Potempa LA. C-reactive protein and cardiovascular disease: an alternative
        view for the clinical practice and basic research.
Am J Kidney Dis. 2006;47:212-222

 26.   Galle J: Die Deutsche Diabetes Dialyse Studie – was unterscheidet 4D von anderen Statin-Studien?
        Diabetes, Metabolism & Heart 2006;2:53-58

 27.   Galle J and Lopau K: Niereninsuffizienz und kardiovaskuläres Risiko – Grundlagen und Interventionsmöglichkeiten.
        Diabetes, Metabolism & Heart 2006;3:3-6

 

28.   Reinecke H, Brandenburg V, Dominiak P, Floege J, Galle J, Geiger H, Grabensee B, de Haan F, Heun K, Ivens K, Kroll J,
        Kutkuhn B, Mann J, Philipp T, Risler T, Strauer B, Thiel W, and Breithardt G. Empfehlungen zur Diagnostik und Behandlung
        von Patienten mit koronarer Herzkrankheit und Niereninsuffizienz: Teil I. Clin Res Cardiol Sppl 2006; 1:8-30

 

29.  Reinecke H, Brandenburg V, Dominiak P, Floege J, Galle J, Geiger H, Grabensee B, de Haan F, Heun K, Ivens K, Kroll J,
        Kutkuhn B, Mann J, Philipp T, Risler T, Strauer B, Thiel W, and Breithardt G. Empfehlungen zur Diagnostik und Behandlung
        von Patienten mit koronarer Herzkrankheit und Niereninsuffizienz: Teil II. Clin Res Cardiol Sppl 2006; 1:103-117

 

  30.  Galle J: Prävention von Röntgen-Kontrastmittel induzierten Nierenschäden. Diabetes, Metabolism & Heart 2008; 17: 37-39

 

  31.  Galle J: Direkte Renininhibition: Therapiealternative bei diabetischer Nephropathie? Diabetes, Metabolism & Heart 2008; 17:379-382

 

  32.  Galle J and Lopau K: Der renovaskuläre Hypertonus - Therapieoptionen aus nephrologischer Sicht. Gefäßchirurgie 2008; 13 (5):323-329.

 

33.  Ritz E, Galle J, and Riegel W. High blood pressure and kidney diseases--an unhealthy combination. Dtsch.Med Wochenschr. 2009; 134 (10):9.

 

34.  Galle J, Helmchen U, Heil G, and Kalb K: Non-Hodgkin-Lymphom und Proteinurie.
   Der Nephrologe 2010; 5:314-318 [
PDF]

 

 35.   Galle J: Renal failure, statins and cardiovascular disease: AURORA confirms 4D.
        Diabetes, Metabolism & Heart 2010;19:201-204 [
PDF]

 

 36.   Galle J: Cardiorenal syndrome.
        Med Klin 2010;105:142-149 [
PDF]

 

 37.   Schneider A, Asmus G, Biggar P, Braun J, Dellanna F, Fiedler R, Galle J, Girndt M, Gondolf K,
         Hahn K,  Koch M, Müller HJ,  Rump LC, Vosskühler A, Winkler R, and Wanner C:
         Hemoglobin cycling in hemodialysis patients. Nephrology Reviews 2010; volume 2:e1 [
PDF]

 

 38.   Galle J: Das EHEC-assoziierte HUS - Thrombotische Mikroangiopathien.
          Klinikarzt  2011;40:458-461 [
PDF]

 

 39.   Brandenburg V, Fliser D, Fliser M, Floege J, Galle J, Girndt M, Haufe CC, Ketteler M, and Wanner C.
          Praxisleitfanden zur Therapie des sHPT Der Nephrologe 2011; 6:274-276 [
PDF]

 

 40.  Alfke H, Galle J, Schorn B: Diagnostische Angiographien bei Patienten mit chronischer Niereninsuffizienz.

        Gefäßchirurgie 2011; 16:598-602

 

 41.   Galle J: 4D, AURORA und nun SHARP: wie ist Cholesterin-senkende Therapie

         bei chronischer Nierenerkrankung zu bewerten? Spektrum der Nephrologie 2012; 1:3-7 [PDF]

 

 42.   Galle J: Die hypertensive Krise: Klinische Abgrenzung maligne Hypertonie vs. HUS/TTP Komplex.

         Spektrum der Nephrologie 2012; 3:13-20 [PDF]

 

 43.    Galle J: Eisenpräparate in der Nephrologie – Produkte, Applikationsformen, und Wirkmechanismen.

         Dialyse Aktuell 2013; 17 (Sppl. 1): S11-S16 [PDF]

 

 


 

 

top of the page

 
Buchartikel

 

1. Pohl U, Busse R, Galle J, Bassenge E. Possible function of endothelial cells as oxygen sensors. In: Acker H, ed. Oxygen
      sensing in tissues
. Berlin-Heidelberg-New York: Springer Verlag; 1988:143-149.

 

2. Galle J, Bassenge E. Effect of native and oxidized low density lipoproteins on vascular tone. In: Wissler, ed. Atherosclerotic
      plaques
. New York: Life Sciences Plenum Press; 1991:273-283.

 

3. Galle J, Bassenge E. Effects of native and oxidized low density lipoproteins on endothelium-dependent and endothelium-
      independent vasomotion. In: Drexler, Zeiher, Bassenge, Just, eds. Endothelial mechanism of vasomotor control. Darmstadt:
      Steinkopff Verlag; 1991:127-142.

 

4. Galle J, Wanner C. Oxidized lipoprotein(a) stimulates production of superoxide radical and inhibits vasodilation. In: Moncada
      S, Stamler J, Gross S, Higgs EA, eds. The Biology of Nitric Oxide . Portland Press; 1996:109-109.

 

5. Galle J, Wanner C. Oxidized LDL and Lp(a) - preparation, modification, and analysis. In: Methods in Molecular Biology, Vol. 108,
      Free Radical and Antioxidant Protocols.Edited
by: Armstrong D,  Totowa, NJ: Humana Press; 1998:119-130 [
PDF].

 

6. Galle J, Wanner C. Nephrotisches Syndrom. In: Classen M, Diehl V, Kochsiek K, eds. Innere Medizin. München: Urban
      &Schwarzenberg; 1998:1261-1262.

 

7. Wanner C, Galle J. Glomeruläre Erkrankungen. In: Classen M, Diehl V, Kochsiek K, eds. Innere Medizin. München:
      Urban&Schwarzenberg; 1998:1262-1270.

 

8. Wanner C, Galle J. Chronische Niereninsuffizienz. In: Classen M, Diehl V, Kochsiek K, eds. Innere Medizin. München:
      Urban&Schwarzenberg; 1998:1292-1300.

 

9. Schramm L, Galle J. Toxische Nephropathien. In: Classen M, Diehl V, Kochsiek K, eds. Innere Medizin. München:
      Urban&Schwarzenberg; 1998:1290-1292.

 

10. Galle J, Heidbreder E, Wanner C. Niere und Hypertonie. In: Classen M, Diehl V, Kochsiek K, eds. Innere Medizin .
      München: Urban&Schwarzenberg; 1998:1300-1312.

 

11. Heermeier K, Heinloth A, Galle J. OxLDL modulates the cell cycle via oxidative stress. In: Yoshikawa T, Toyokuni S,
       Yamamoto Y, Naito Y, eds.
Free Radicals in Chemistry, Biology and Medicine . London: OICA International; 2001. Chapter
       31:299-304

 

12. Galle J, Quaschning T. Angiotensin II and atherosclerosis - relevance for renal disease. In: Wolf G ed. The renin angiotensin
       system and progression of renal disease.
Karger Basel 2001;Vol 135, Chapter 19:235-249
[PDF]

 

13.   Galle J and C. Wanner. Oxidativer Stress, Inflammation, und Atherosklerose. In: Dialyseverfahren in Klinik

       und Praxis, edited by W. Hörl and C. Wanner, Stuttgart:Thieme Verlag, 2003; Vol. 6, Kapitel 31:402-407

 

14.   Galle J, Quaschning T, Seibold S. Oxidative stress, lipoproteins and angiotensin II – the unholy triade in the pathogenesis of
        renal fibrosis. In: Razzaque M ed. Fibrogenesis: Cellular and Molecular Events. Landes Bioscience 2004; Chapter 3:27-37
[PDF]
 

15:   Galle J, Wanner C. Nephrotisches Syndrom. In: Classen M, Diehl V, Kochsiek K, eds. Innere Medizin. München:
Urban &Schwarzenberg; 2007 (in press)
 

16.    Galle J, Lopau K: Chronische Niereninsuffizienz. In: Facharzt Nephrologie, edited by T. Risler and K. W. Kuehn, Muenchen:Elsevier Urban & Fischer, 2008, 563-630.

 

17.   Galle J, Wanner C. Nephrotisches Syndrom. In: Innere Medizin, edited by M. Boehm, M. Hallek, and W. Schmiegel, Muenchen:Urban&Fischer, 2009, p. 1242-1243.

 

18.    Wanner C, Galle J. Glomeruläre Erkrankungen. In: Innere Medizin, edited by M. Boehm, M. Hallek, and W. Schmiegel, Muenchen:Urban & Fischer, 2009, p. 1244-1251.

 

19.    Wanner C, Galle J.  Chronische Niereninsuffizienz. In: Innere Medizin, edited by M. Boehm, M. Hallek, and W. Schmiegel, Muenchen:Urban & Fischer, 2009, p. 1277-1281.

 

20.    Galle J. Toxische Nephropathien. In: Innere Medizin, edited by M. Boehm, M. Hallek, and W. Schmiegel, Muenchen:Urban & Fischer, 2009, p. 1274-1276.

 

21.    Galle J and Wanner C. Niere und Hypertonie. In: Innere Medizin, edited by M. Boehm, M. Hallek, and W. Schmiegel, Muenchen:Urban & Fischer, 2009, p. 251-266.

 

22.     Fliser D and Galle J. Das rekombinante humane Erythropoetin als Beispiel eines Biotechnologieprodukts. In: Rekombinante Arzneimittel, edited by I. Kraemer and W. Jelkmann, Heidelberg: Springer Medizin Verlag, 2011, p. 37-44.

 

23.    Galle J. Hypertensive Entgleisung. In: Internistische Intensivmedizin und Notfallmedizin, edited by Weilemann, Lorenz & Voigtländer, Heidelberg: Springer Medizin Verlag, 2011, p. 221-225

 

 

 

top of the page